Luke Z. Li, HBSc,a,b;Tong Yang, MD,a,b,c; Marc R. Matrana, MD, MS, FACP,a,b,d aThe University of Queensland Faculty of Medicine, Ochsner Clinical School; bOchsner Clinical School, Ochsner Medical Center; cOchsner Department of Pathology and Laboratory Medicine; dOchsner Cancer Institute, New Orleans, LA
DISCLOSURES: The authors report no disclosures or conflicts of interest.
CORRESPONDENCE: Marc R. Matrana, MD, MS, FACP, mamatrana@ochsner.org
ACKNOWLEDGMENTS: Thom Smilari, MD, Ochsner Department of Pathology and Laboratory Medicine; Shams K. Halat, MD, Tulane University School of Medicine, New Orleans, LA. Additional cytopathologic testing performed by Maxwell L. Smith, MD, Mayo Clinic, Arizona.
Etiology of tumorigenesis in cases of angiosarcoma arising in patients with a history of benign hemangioma may benefit prognostication and inform treatment selection in the future. Owing to long latent periods, radiation-associated angiosarcoma incidence may rise, as radiation therapy for benign hemangioma was recently routine. Future research may provide insight into disease progression and possibly predict the risk of angiosarcoma in patients with long-standing benign disease. TSJ
